| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $923,550 ) |
| | 2026 | 2026 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R44AG084351 | Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts | 000 | 3 | NIH | 7/10/2026 | $923,550 |
|
| Issue Date FY: 2025 ( Subtotal = $1,721,470 ) |
| | 2025 | 2025 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R44AG084351 | Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts | 000 | 2 | NIH | 8/14/2025 | $1,364,162 |
| | 2025 | 2025 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43EY036695 | Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy | 000 | 1 | NIH | 7/25/2025 | $358,065 |
| | 2025 | 2024 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43DK137624 | Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease | 000 | 1 | NIH | 12/4/2024 | $0 |
| | 2025 | 2024 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43DK137624 | Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease | 001 | 1 | NIH | 8/27/2025 | -$182 |
| | 2025 | 2024 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43GM154502 | An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts | 000 | 1 | NIH | 8/18/2025 | -$77 |
| | 2025 | 2023 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43AA030937 | An enzyme-based assay for the detection of acetaldehyde-protein adducts | 000 | 1 | NIH | 11/7/2024 | -$19 |
| | 2025 | 2023 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43AG084351 | Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts | 000 | 1 | NIH | 11/26/2024 | -$479 |
|
| Issue Date FY: 2024 ( Subtotal = $670,770 ) |
| | 2024 | 2024 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43GM154502 | An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts | 000 | 1 | NIH | 7/1/2024 | $346,755 |
| | 2024 | 2024 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43GM154502 | An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts | 001 | 1 | NIH | 9/24/2024 | $0 |
| | 2024 | 2024 | REVEL PHARMACEUTICALS INC. | 2325 3RD ST STE 214 | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43DK137624 | Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease | 000 | 1 | NIH | 4/29/2024 | $324,015 |
|
| Issue Date FY: 2023 ( Subtotal = $549,760 ) |
| | 2023 | 2023 | REVEL PHARMACEUTICALS INC. | 2325 3RD STREET | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43AA030937 | An enzyme-based assay for the detection of acetaldehyde-protein adducts | 000 | 1 | NIH | 7/20/2023 | $272,137 |
| | 2023 | 2023 | REVEL PHARMACEUTICALS INC. | 2325 3RD STREET | SAN FRANCISCO | CA | 94107-3197 | SAN FRANCISCO | USA | R43AG084351 | Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts | 000 | 1 | NIH | 8/14/2023 | $277,623 |
|
|
